Xuzhou Thingdi Pharmaceutical Co., Ltd.

Phase IIa evaluates the efficacy, safety, and pharmacokinetic characteristics of 3D1002 50, 100, and 150 mg po q12h in the treatment of patients with moderate to severe cancer pain. Phase IIb compares the efficacy and safety of 3D1002 combined with oxycodone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets alone in the treatment of patients with moderate to severe cancer pain by studying the total pain intensity difference index 14 days after the first drug treatment, and evaluates the drug interaction between 3D1002 and oxycodone hydrochloride extended-release tablets.